Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol adjunctive therapy for seizures associated with Lennox-Gastaut syndrome
2014-002941-23Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Cannabidiol adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: Mean percentage change from baseline in drop seizure frequency. Started Mar 2015; status: completed.
02
Drugs
cannabidiol
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2014-002941-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002941-23.